Collaboration in Infectious Disease Research

Our innovation is founded by our mission to discover and develop novel therapeutics and vaccines to treat and cure infectious diseases worldwide, improving treatment outcomes and patients’ lives. With a strong heritage in collaborative partnerships and a proven track record in the rapid development of and access to innovative new treatments, we aim to further our success and become a global leader in infectious diseases. By combining interest, efforts and expertise in science, our goal is to truly care for the world one person at a time, improve public health and help people to live longer and healthier lives.

At Janssen, we believe that collaboration and sharing of knowledge and capabilities are necessary to solve today’s complex medical challenges. Here are some of our recent collaborations in Infectious Diseases & Vaccines.

We are working with Medivir AS to develop an NS3/4A protease inhibitor to treat chronic hepatitis C (HCV). This drug is being developed in combination with several other agents.

In collaboration with ViiV Healthcare, we are developing a novel single-tablet regimen for the maintenance treatment of people living with human immunodeficiency virus (HIV). We are further investigating development of this drug combination for pediatric use.

We have an agreement with Gilead Sciences, Inc. (Gilead) to develop two single-tablet regimens for the treatment of people living with human immunodeficiency virus (HIV): A protease inhibitor-based regimen, for which Janssen will be primarily responsible, and a second non-nucleoside reverse transcriptase inhibitor-based regimen, for which Gilead will be primarily responsible.